This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies. The main focus of this book is to review current and emerging heart failure therapies and potential targets for treatment.
This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies. The main focus of this book is to review current and emerging heart failure therapies and potential targets for treatment.
Introduction.- Epidemiology.- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine.- Beta3 agonists.- Novel MRAs.- pGCs and Natriuretic peptides.- sGC stimulators.- PDE's.- Adenosin and A1 Agonists.- Myosin heavy chain / Troponin.- Stem cells.- Diuretics and Vasopressin.- GeneTherapy.- RNA-based therapies and micro RNAs.- Cardiac myosin activation using gene therapy.- Bendavia - mitochondrial therapies.- WNT signaling.- Anticoagulation therapy and NOACS in HF.- Potassium Binders.- Iron.
Introduction.- Epidemiology.- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine.- Beta3 agonists.- Novel MRAs.- pGCs and Natriuretic peptides.- sGC stimulators.- PDE’s.- Adenosin and A1 Agonists.- Myosin heavy chain / Troponin.- Stem cells.- Diuretics and Vasopressin.- GeneTherapy.- RNA-based therapies and micro RNAs.- Cardiac myosin activation using gene therapy.- Bendavia – mitochondrial therapies.- WNT signaling.- Anticoagulation therapy and NOACS in HF.- Potassium Binders.- Iron.
Introduction.- Epidemiology.- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine.- Beta3 agonists.- Novel MRAs.- pGCs and Natriuretic peptides.- sGC stimulators.- PDE's.- Adenosin and A1 Agonists.- Myosin heavy chain / Troponin.- Stem cells.- Diuretics and Vasopressin.- GeneTherapy.- RNA-based therapies and micro RNAs.- Cardiac myosin activation using gene therapy.- Bendavia - mitochondrial therapies.- WNT signaling.- Anticoagulation therapy and NOACS in HF.- Potassium Binders.- Iron.
Introduction.- Epidemiology.- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine.- Beta3 agonists.- Novel MRAs.- pGCs and Natriuretic peptides.- sGC stimulators.- PDE’s.- Adenosin and A1 Agonists.- Myosin heavy chain / Troponin.- Stem cells.- Diuretics and Vasopressin.- GeneTherapy.- RNA-based therapies and micro RNAs.- Cardiac myosin activation using gene therapy.- Bendavia – mitochondrial therapies.- WNT signaling.- Anticoagulation therapy and NOACS in HF.- Potassium Binders.- Iron.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
